Scandion Oncology Q1 2024: Funding for CORIST part 3 extension - Redeye

Redeye comments on Scandion Oncology’s Q1 2024 report, shortly after the company announced final terms of its rights issue to fund its CORIST part 3 extension trial. The rights issue’s subscription price amounts to SEK0.64 per unit or SEK0.16 per share and the company secured cSEK31m of up to cSEK61m in initial proceeds in subscription undertakings and guarantees. We adjust our estimates and valuation for our expected outcome of the rights issue.

Länk till analysen i sin helhet: https://www.redeye.se/research/1011302/scandion-oncology-q1-2024-funding-for-corist-part-3-extension?utm_source=finwire&utm_medium=RSS